FNORX | FTCNX | FNORX / FTCNX | |
Total Expense Ratio | 0.87 | 1.57 | 55% |
Annual Report Gross Expense Ratio | 0.87 | 1.57 | 55% |
Fund Existence | 30 years | 18 years | - |
Gain YTD | 18.749 | 14.110 | 133% |
Front Load | N/A | 4% | - |
Min. Initial Investment | 0 | 0 | - |
Min. Initial Investment IRA | N/A | N/A | - |
Net Assets | 332M | 996M | 33% |
Annual Yield % from dividends | 3.49 | 0.68 | 516% |
Returns for 1 year | -1.73 | 12.77 | -14% |
Returns for 3 years | 35.03 | 15.39 | 228% |
Returns for 5 years | 48.81 | 61.70 | 79% |
Returns for 10 years | 61.44 | 54.87 | 112% |
1 Day | |||
---|---|---|---|
ETFs / NAME | Price $ | Chg $ | Chg % |
BBC | 19.76 | 0.18 | +0.91% |
Virtus LifeSci Biotech Clinical Trls ETF | |||
OPP | 8.42 | 0.01 | +0.12% |
RiverNorth/DoubleLine Strategic Opportunity Fund | |||
DEED | 20.92 | -0.02 | -0.10% |
First Trust Securitized Plus ETF | |||
ILTB | 48.34 | -0.11 | -0.23% |
iShares Core 10+ Year USD Bond ETF | |||
UTG | 34.55 | -0.20 | -0.58% |
Reaves Utility Income Fund |